載入中
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
前收盤價
US$36.83
−US$0.15 · -0.41%
盤中時間採用ET。市場資料可能有所延遲。
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
日內區間
目前US$36.83
52週區間
目前US$36.83
盤中時間採用ET。市場資料可能有所延遲。
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
日內區間
目前US$36.83
52週區間
目前US$36.83
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.1億 USD | 9039.8萬 USD | 8271.3萬 USD | 6435.7萬 USD | 4804.2萬 USD |
| 銷貨成本 | 1244.7萬 USD | 888.1萬 USD | 936.1萬 USD | 765.4萬 USD | 515.7萬 USD |
| 毛利 | 9734.1萬 USD | 8151.7萬 USD | 7335.2萬 USD | 5670.3萬 USD | 4288.5萬 USD |
| 研究與開發 | 6710.7萬 USD | 5714.5萬 USD | 4561.4萬 USD | 5290.6萬 USD | 4764.2萬 USD |
| 銷售、一般及管理費用 | 1.55億 USD | — | 9327.4萬 USD | 8283.8萬 USD | — |
| 營業費用 | 2.22億 USD | 1.78億 USD | 1.39億 USD | 1.36億 USD | 1.35億 USD |
| 利息收入 | 596.5萬 USD | 890.1萬 USD | 264.1萬 USD | 93.8萬 USD | 36.5萬 USD |
| 利息支出 | 3384.8萬 USD | 1252.1萬 USD | 1471.5萬 USD | 843.8萬 USD | 1744.4萬 USD |
| 折舊和攤銷 | 241.1萬 USD | 118.6萬 USD | 170.5萬 USD | 181.7萬 USD | 177.3萬 USD |
| 營業利益 | −1.25億 USD | −9678.2萬 USD | −6553.6萬 USD | −7904.1萬 USD | −9229.2萬 USD |
| 淨利 | −1.53億 USD | −1.27億 USD | −1.02億 USD | −1.1億 USD | −1.11億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$56.60
上漲空間 53.68%報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM4148.12萬0.05%787.4億 USD0.19%US$278.94+0.49%
iShares Russell 2000 Growth ETFIWO1255.15萬0.09%139.17億 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB1189.45萬0.11%108.2億 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO1054.67萬0.06%180億 USD0.06%US$112.66+0.50%
Fidelity Enhanced Small Cap ETFFESM782.88萬0.12%64.1億 USD0.28%US$45.46+0.46%
State Street SPDR Portfolio Developed World ex-US ETFSPDW695.7萬0.02%404.62億 USD0.03%US$49.98+0.64%
Vanguard Health Care ETFVHT510.31萬0.02%220億 USD0.09%US$319.01+1.64%
iShares Micro-Cap ETFIWC496.96萬0.38%13.17億 USD0.60%US$183+0.11%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMState Street SPDR Portfolio Developed World ex-US ETFSPDWVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
